Methyl-CpG-Binding Protein 2
"Methyl-CpG-Binding Protein 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A DNA-binding protein that interacts with methylated CPG ISLANDS. It plays a role in repressing GENETIC TRANSCRIPTION and is frequently mutated in RETT SYNDROME.
| Descriptor ID |
D051783
|
| MeSH Number(s) |
D12.776.260.536 D12.776.660.235.550 D12.776.664.235.700
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Methyl-CpG-Binding Protein 2".
Below are MeSH descriptors whose meaning is more specific than "Methyl-CpG-Binding Protein 2".
This graph shows the total number of publications written about "Methyl-CpG-Binding Protein 2" by people in this website by year, and whether "Methyl-CpG-Binding Protein 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 3 | 3 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 5 | 5 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 5 | 5 |
| 2005 | 2 | 0 | 2 |
| 2006 | 3 | 2 | 5 |
| 2007 | 4 | 0 | 4 |
| 2008 | 6 | 1 | 7 |
| 2009 | 5 | 4 | 9 |
| 2010 | 4 | 3 | 7 |
| 2011 | 3 | 3 | 6 |
| 2012 | 7 | 1 | 8 |
| 2013 | 3 | 4 | 7 |
| 2014 | 3 | 2 | 5 |
| 2015 | 11 | 3 | 14 |
| 2016 | 8 | 3 | 11 |
| 2017 | 2 | 0 | 2 |
| 2018 | 6 | 3 | 9 |
| 2019 | 1 | 3 | 4 |
| 2020 | 5 | 0 | 5 |
| 2021 | 4 | 2 | 6 |
| 2022 | 1 | 2 | 3 |
| 2023 | 1 | 6 | 7 |
| 2024 | 5 | 2 | 7 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Methyl-CpG-Binding Protein 2" by people in Profiles.
-
Comprehensive assessment reveals numerous clinical and neurophysiological differences between MECP2-allelic disorders. Ann Clin Transl Neurol. 2025 Feb; 12(2):433-447.
-
Structural variant allelic heterogeneity in MECP2 duplication syndrome provides insight into clinical severity and variability of disease expression. Genome Med. 2024 Dec 18; 16(1):146.
-
Acute MeCP2 loss in adult mice reveals transcriptional and chromatin changes that precede neurological dysfunction and inform pathogenesis. Neuron. 2025 Feb 05; 113(3):380-395.e8.
-
Modeling antisense oligonucleotide therapy in MECP2 duplication syndrome human iPSC-derived neurons reveals gene expression programs responsive to MeCP2 levels. Hum Mol Genet. 2024 11 08; 33(22):1986-2001.
-
MECP2 Variants in Males: More Common than Previously Appreciated. Pediatr Neurol. 2024 Dec; 161:263-267.
-
Clinical Features and Disease Progression in Older Individuals with Rett Syndrome. Genes (Basel). 2024 Aug 22; 15(8).
-
Autoimmune and neuropsychiatric phenotypes in a Mecp2 transgenic mouse model on C57BL/6 background. Front Immunol. 2024; 15:1370254.
-
Sensory experiences questionnaire unravels differences in sensory profiles between MECP2-related disorders. Autism Res. 2024 04; 17(4):775-784.
-
Generation of five induced pluripotent stem cell lines from patients with MECP2 Duplication Syndrome. Stem Cell Res. 2024 02; 74:103292.
-
A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels. Genes Dev. 2023 10 01; 37(19-20):883-900.